Equities

Daxor Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DX5:FRA

Daxor Corp

Actions
  • Price (EUR)10.10
  • Today's Change-0.10 / -0.98%
  • Shares traded2.00
  • 1 Year change+43.26%
  • Beta0.0368
Data delayed at least 15 minutes, as of Feb 10 2026 07:04 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

  • Revenue in USD (TTM)66.31k
  • Net income in USD1.80m
  • Incorporated1971
  • Employees37.00
  • Location
    Daxor Corp107 Meco LaneOAK RIDGE 37830United StatesUSA
  • Phone+1 (865) 425-0555
  • Fax+1 (212) 244-0806
  • Websitehttps://www.daxor.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.